Close Menu

NEW YORK (GenomeWeb) – OpGen reported after the close of the market on Tuesday that its third quarter revenues fell 2 percent year over year.

For the three months ended Sept. 30, the firm reported total revenues of $745,144, down from $759,663 in Q3 2016. Product sales fell to $729,742 from $730,325 in the year-ago quarter, while lab services revenues fell to $9,070 from $23,036, and collaboration revenues remained flat at $6,302.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.